LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU=Hehlmann R
  2. AU="Azzopardi, Nicolas"
  3. AU="Surić-Mihić Marija"
  4. AU=Cismasiu Valeriu B
  5. AU="Töpfer, Änne"
  6. AU="Lemcke, Johannes"
  7. AU=Cousins Emily
  8. AU="Clarke Aileen"
  9. AU="Aparecido Corrêa, Nivaldo"
  10. AU="Meng-Ju Wang"
  11. AU=Verrills Paul
  12. AU="Chaudhari, Amol"
  13. AU="Planagumà, Jesús"
  14. AU="de Rezende, Grazielli Rocha"
  15. AU="Mohadeseh NEZAM"
  16. AU="Daniel Pecos-Martín"
  17. AU="Gentle, Popular"
  18. AU=Wang Jirui
  19. AU="Bielik, Martin"
  20. AU="Simon A.F. Darroch"
  21. AU="Suzuki, Kenichi G N"
  22. AU="Hu, Yizhong"
  23. AU=Sasaki Kotaro
  24. AU=Abd-Elsayed Alaa
  25. AU="Jung, Hee-Jun"
  26. AU="Struckmann, Stephan"
  27. AU=Coward Richard
  28. AU="Ghazizadeh, Shabnam"
  29. AU="Rebecca A Butcher"
  30. AU="Kimberlyn Roosa"
  31. AU=Chian Ri-Cheng
  32. AU="Alzalzalah, Sayed"
  33. AU=Kaufman Jonathan J
  34. AU="Kim, Jin K"
  35. AU="Zevakov, S A"
  36. AU="Sui Phang"
  37. AU="Kolomeichuk, Lilia V"
  38. AU="Sabuj Kanti Mistry"
  39. AU="Basurto-Lozada, Daniela"
  40. AU="Takashima, Shin-Ichiro"
  41. AU="Teresinha Leal"
  42. AU="Angélique B van 't Wout"
  43. AU="Roberts, Nicholas J"
  44. AU="Chauhan, Gaurav B"
  45. AU=Hanjaya-Putra Donny
  46. AU=Powell James
  47. AU="Russell, Todd"
  48. AU=Forth Scott
  49. AU="Kreutzer, Susanne" AU="Kreutzer, Susanne"
  50. AU="St John, Maie"
  51. AU=Gerhardy A
  52. AU="Qi, Huixin"
  53. AU="Dobosiewicz, May"
  54. AU="Srivastava, Rakesh"
  55. AU="Grevtsov K.I."

Suchergebnis

Treffer 1 - 10 von insgesamt 566

Suchoptionen

  1. Buch ; Online ; E-Book: Chronic myeloid leukemia

    Hehlmann, Rüdiger

    (Hematologic malignancies)

    2016  

    Verfasserangabe Rüdiger Hehlmann editor
    Serientitel Hematologic malignancies
    Schlagwörter Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology ; Antineoplastic Agents / therapeutic use
    Sprache Englisch
    Umfang 1 Online-Ressource (x, 255 Seiten), Illustrationen, 26 cm
    Verlag Springer
    Erscheinungsort Cham
    Erscheinungsland Schweiz
    Dokumenttyp Buch ; Online ; E-Book
    Anmerkung Includes bibliographical references
    Bemerkung Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT019454875
    ISBN 978-3-319-33198-0 ; 9783319331973 ; 3-319-33198-1 ; 3319331973
    Datenquelle ZB MED Katalog Medizin, Gesundheit, Ernährung, Umwelt, Agrar

    Kategorien

  2. Buch: Advances in biology and therapy of chronic myeloid leukaemia

    Hehlmann, R.

    (Best practice & research : Clinical haematology ; 22,3)

    2009  

    Verfasserangabe R. Hehlmann, guest ed
    Serientitel Best practice & research : Clinical haematology ; 22,3
    Best practice & research
    Best practice & research ; Clinical haematology
    Überordnung Best practice & research
    Best practice & research ; Clinical haematology
    Sprache Englisch
    Umfang S. 284 - 474 : Ill., graph. Darst.
    Verlag Elsevier
    Erscheinungsort Amsterdam
    Erscheinungsland Niederlande
    Dokumenttyp Buch
    HBZ-ID HT016183850
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: What is the right dosage of dasatinib for treating chronic myeloid leukaemia?

    Hehlmann, Rüdiger

    British journal of haematology

    2021  Band 194, Heft 2, Seite(n) 234

    Mesh-Begriff(e) Dasatinib ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myeloid ; Protein Kinase Inhibitors
    Chemische Substanzen Protein Kinase Inhibitors ; Dasatinib (RBZ1571X5H)
    Sprache Englisch
    Erscheinungsdatum 2021-06-30
    Erscheinungsland England
    Dokumenttyp Journal Article ; Comment
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.17618
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies.

    Hehlmann, Rüdiger / Lauseker, Michael

    Leukemia

    2024  Band 38, Heft 2, Seite(n) 465–466

    Mesh-Begriff(e) Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myeloid ; Chronic Disease ; Complementary Therapies
    Sprache Englisch
    Erscheinungsdatum 2024-01-13
    Erscheinungsland England
    Dokumenttyp Letter ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-024-02139-4
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Chronic Myeloid Leukemia in 2020.

    Hehlmann, Rüdiger

    HemaSphere

    2020  Band 4, Heft 5, Seite(n) e468

    Abstract: New insights have emerged from maturing long-term academic and commercial clinical trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of response has unexpectedly proved less important than hitherto thought, does not predict ... ...

    Abstract New insights have emerged from maturing long-term academic and commercial clinical trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of response has unexpectedly proved less important than hitherto thought, does not predict survival, and is of unclear relevance for treatment-free remission (TFR). Serious and cumulative toxicity has been observed with tyrosine kinase inhibitors that had been expected to replace imatinib. Generic imatinib has become cost-effective first-line treatment in chronic phase despite chronic low-grade side-effects in many patients. Earlier recognition of end-phase by genetic assessment might improve prospects for blast crisis (BC). TFR has become an important new treatment goal of CML. To reflect this new situation ELN has recently revised and updated its recommendations for treating CML. After a brief review of 175 years of CML history this review will focus on recent developments and on current evidence for treating CML in 2020.
    Sprache Englisch
    Erscheinungsdatum 2020-09-30
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ISSN 2572-9241
    ISSN (online) 2572-9241
    DOI 10.1097/HS9.0000000000000468
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel: The New ELN Recommendations for Treating CML.

    Hehlmann, Rüdiger

    Journal of clinical medicine

    2020  Band 9, Heft 11

    Abstract: After normal survival has been achieved in most patients with chronic myeloid leukemia (CML), a new goal for treating CML is survival at good quality of life, with treatment discontinuation in sustained deep molecular response (DMR; ... ...

    Abstract After normal survival has been achieved in most patients with chronic myeloid leukemia (CML), a new goal for treating CML is survival at good quality of life, with treatment discontinuation in sustained deep molecular response (DMR; MR
    Sprache Englisch
    Erscheinungsdatum 2020-11-16
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm9113671
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Advancing a field by building consortia: The example of the European LeukemiaNet.

    Hehlmann, Rüdiger

    Cancer

    2018  Band 124, Heft 6, Seite(n) 1100–1104

    Mesh-Begriff(e) Europe ; Humans ; International Cooperation ; Leukemia/diagnosis ; Leukemia/therapy ; Medical Oncology/organization & administration ; Societies, Medical
    Sprache Englisch
    Erscheinungsdatum 2018-02-16
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.31199
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Buch ; Online: Faculty Opinions recommendation of SARS-CoV-2 vaccines in development.

    Hehlmann, Ruediger

    Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

    2020  

    Schlagwörter covid19
    Verlag Faculty Opinions Ltd
    Erscheinungsland uk
    Dokumenttyp Buch ; Online
    DOI 10.3410/f.738713957.793580075
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Prognostic relevance of CCAs/Ph

    Hehlmann, Rüdiger

    Blood

    2017  Band 130, Heft 19, Seite(n) 2046–2047

    Mesh-Begriff(e) Arachnodactyly ; Contracture ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Prognosis
    Sprache Englisch
    Erscheinungsdatum 2017-11-09
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2017-09-804054
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Survival with chronic myeloid leukaemia after failing milestones.

    Lauseker, Michael / Hehlmann, Rüdiger / Hochhaus, Andreas / Saußele, Susanne

    Leukemia

    2023  Band 37, Heft 11, Seite(n) 2231–2236

    Abstract: Therapy after failing response milestones in CML is controversial. Risks associated with comorbidities, drug toxicities or transplantation may preclude switching to another tyrosine kinase inhibitor (TKI) or other treatments. No information on long-term ... ...

    Abstract Therapy after failing response milestones in CML is controversial. Risks associated with comorbidities, drug toxicities or transplantation may preclude switching to another tyrosine kinase inhibitor (TKI) or other treatments. No information on long-term survival of failing patients is available. To systematically analyse survival after reaching, or not reaching, response milestones, 1342 patients from CML-study IV with newly diagnosed CML in chronic phase and regular molecular tests were studied. Landmark survival analyses were done by <0.1%, 0.1-1%, >1-10% and >10% BCR::ABL1
    Mesh-Begriff(e) Humans ; Middle Aged ; Fusion Proteins, bcr-abl/genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Survival Analysis
    Chemische Substanzen Fusion Proteins, bcr-abl (EC 2.7.10.2) ; Protein Kinase Inhibitors
    Sprache Englisch
    Erscheinungsdatum 2023-09-19
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-023-02028-2
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang